Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

Abstract

GM-CSF does not reduce the incidence of complications from myelosuppression of aggressive chemotherapy. Dose intensification of V-ICE to a 3-week schedule in SCLC is not associated with increased toxicity, but appears to improve survival significantly. Future studies should aim to deliver chemotherapy in maximal-tolerated dose-intensities.

Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma

“…This percentage is in line with that observed in SCLC studies 34,35 that increased chemotherapy DI regardless of hematopoietic growth factor support. Dose intensification with hematopoietic growth factor support has not been shown to increase survival in chemosensitive tumors in patients with carcinoma of the testis, SCLC, ovarian carcinoma, lymphoma, or bladder carcinoma.…”

Chemotherapy in small cell lung cancer

“…Similarly, outcome was also negative in a joint European trial on increased dose-intensity plus GM-CSF in limited-stage SCLC [54]. In a two-bytwo factorial design patients were firstly randomized to vincristine, iphosphamide, carbaplatin, etoposide (VICE) chemotherapy every 3 weeks or every 4 weeks and secondly randomized to treatment with GM-CSF or not for 14 days in each cycle (table 6).…”

Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses

“…In the trial by Steward et al [14], patients were randomized to six cycles of V-ICE at fixed intervals, either every 3 weeks or every 4 weeks. In this study, survival was a secondary endpoint.…”